Ibutilide

Circulation

Volumn 97, Issue 5, 1998, Pages 493-497

  Murray, Katherine T ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular Drugs; Drugs; Fibrillation; Ibutilide

Indexed keywords

IBUTILIDE FUMARATE;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; FIRST PASS EFFECT; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BLOCK; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; TERATOGENICITY; TORSADE DES POINTES;

EID: 0032502027     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.5.493     Document Type: Article

References (41)

1. + current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99-108.
2. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds: a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol. 1993;234:43-53.
3. Lee KS, Gibson JK. Unique ionic mechanism of action of ibutilide on freshly isolated heart cells. Circulation. 1995;92:2755-2757.
4. Kr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol. 1995;25:336-340.
5. Kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995;91:1799-1806.
6. Buchanan LV, LeMay RJ, Gibson JK. Comparison of the class III agents d, l sotalol HCl and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effects. Pacing Clin Electrophysiol. 1996;19:687. Abstract.
7. Cimini MG, Brunden MN, Gibson JK. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol. 1992;222:93-98.
8. VanderLugt JT, Gaylor SK, Wakefield LK, Jungbluth GL, Walters RR, Kabell GG. Effects of ibutilide fumarate, a new class III antiarrhythmic agent, in man. Clin Pharmacol Ther. 1991;49:188. Abstract.
9. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissner MC, Zoble RG, Wakefield LK, Perry KT, VanderLugt JT. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28: 130-136.
10. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613-1621.
11. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM, and the SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation. 1996;94:1996-2012.
12. Buchanan LV, Kabell GG, Gibson JK. Comparison of class III agents in a canine model of proarrhythmia. J Am Coll Cardiol. 1993;21:248A. Abstract.
13. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, D-sotalol, clofilium, E- 4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol. 1993;22:540-549.
14. Buchanan LV, Turcotte UM, Kabell GG, Gibson JK. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol. 1993;22:10-14.
15. Buchanan LV, Kabell G, Gibson JK. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J Cardiovasc Pharmacol 1995;25:539-544.
16. Buchanan LV, LeMay RJ, Walters RR, Hsu CY, Brunden MN, Gibson JK. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol. 1996;7:113-119.
17. Nabih MA, Prcevski P, Fromm BS, Lavine SJ, Elnabtity M, Munir A, Steinman RT, Meissner MD, Lehmann MH. Effect of ibutilide, a new class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pacing Clin Electrophysiol. 1993;16:1975-1983.
18. Stambler BS, Wood MA, Ellenbogen KA. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol. 1996;77:960-966.
19. Inoue H, Yamashita T, Nozaki A, Sugimoto T. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol. 1991;18:1098-1104.
20. Buchanan LV, Kabell G, Turcotte UM, Brunden MN, Gibson JK. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. J Cardiovasc Pharmacol. 1992;19:256-263.
21. Wesley RC Jr, Farkhani F, Morgan D, Zimmerman D. Ibutilide: enhanced defibrillation via plateau sodium current activation. Am J Physiol. 1993;264: H1269-H1274.
22. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol. 1996;78:12-16.
23. Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, VanderLugt JT. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol. 1996;78:42-45.
24. Corvert Prescribing Information. Kalamazoo, Mich:. The Upjohn Company; 1996. Abstract.
25. Marks TA, Terry RD. Developmental toxicity of ibutilide fumarate in rats. Teratology. 1994;49:406. Abstract.
26. Jungbluth GL, VanderLugt JT, Welshman IR, Dietz AJ. Relationship between subject age and QTc interval prolongation induced by the class III antiarrhythmic drug ibutilide. Clin Pharmacol Ther. 1996;49:164. Abstract.
27. Guo GB, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Call Cardiol. 1996;27:1083-1089.
28. Mattioni T, Denker S, Riggio D, Smith J, Welch S. Perry K, Wakefield L, VanderLugt J. Efficacy and safety of intravenous ibutilide in the treatment of atrial flutter and atrial fibrillation following valvular or coronary artery bypass surgery. Pacing Clin Electrophysiol. 1997;20:1059. Abstract.
29. Wood M, Stambler B, Gillian D, Ellenbogen K, Perry K, Wakefield L, Vanderlugt J. and the Ibutilide Investigators. Suppression of inducible ventricular tachycardia by intravenous ibutilide in patients with coronary artery disease. Pacing Clin Electrophysiol. 1996;19:618. Abstract.
30. Anderson JL. Acute treatment of atrial fibrillation and flutter. Am J Cardiol. 1996;78:17-21.
31. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion, Am Heart J. 1983;106:501-504.
32. Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J. 1980;44:589-595.
33. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127-1131.
34. Sung RJ, Tan HL, Karagounis L, Hanyok JJ, Falk R, Platia E, Das G, Hardy SA, for the Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J. 1995;129:739-748.
35. Bianconi L, Dinelli M, Papalardo A, Richiardi E, Castro A, Alboni P, Santini M, Dalrymple HW, Radula D. Comparison of intravenously-administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: a multi-centered, randomized, double-blind, placebo-controlled study. Circulation. 1995;92(suppl I):I-774. Abstract.
36. Capucci A, Villiani GQ, on behalf of the SATE Group Investigators. Propafenone oral loading dose plus digitalis in converting atrial fibrillation to sinus rhythm: a placebo-controlled multicenter study. Circulation. 1995; 92(suppl I):I-775. Abstract.
37. Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn GH, Perry KT, VanderLugt JT, Kowey PR. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. Pacing Clin Electrophysiol. 1996;19:608. Abstract.
38. Stambler BS, Wood MA, Belz MK, Sperry RE, VanderLugt JT, Ellenbogen KA. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: enhanced efficacy of ibutilide, a new class III antiarrhythmic drug. Circulation. 1993;88(suppl I):I-445. Abstract.
39. Kowey PR, VanderLugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol. 1996;78:46-52.
40. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991;68:41-46.
41. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med. 1997;336:1429-1434.